LANGENFELD v. ELI LILLY AND COMPANY

What this case is about

This lawsuit alleges that Eli Lilly manufactured and sold a pharmaceutical product that caused personal injury or harm to the plaintiff and others in similar situations. The plaintiff claims that Eli Lilly's drug was defective or unsafe, and that the company failed to adequately warn consumers about the risks associated with taking the medication. The lawsuit is filed as a class action, meaning the lead plaintiff seeks to represent a broader group of people who were allegedly harmed by the same product under similar circumstances. The case is being heard in federal court based on diversity jurisdiction, meaning the parties are from different states and the amount in dispute meets the federal threshold. The proposed class likely includes individuals who used the specific Eli Lilly medication and suffered health-related injuries as a result.

What happens next

The case is in its earliest stage. The defendant has not yet responded. Class certification — the court's decision on whether the case can proceed as a class action — typically takes 12 to 24 months after filing. See our FAQ for how class actions work and what it means to be a class member.

Source: CourtListener docket entry. This summary was generated automatically from the public docket and has not been reviewed by an attorney. It may contain errors and may not reflect subsequent filings. Published by Access Law Group; responsible attorney Bogdan Enica, Esq..